Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma

Open access
Field, Kathryn M., Simes, John, Nowak, Anna K., Cher, Lawrence, Wheeler, Helen, Hovey, Elizabeth J., Brown, Christopher S.B., Barnes, Elizabeth H., Sawkins, Kate, Livingstone, Ann, Freilich, Ron, Phal, Pramit M., Fitt, Greg, CABARET/COGNO investigators, Rosenthal, Mark A. · 2015 · Neuro-Oncology

Abstract

BACKGROUND: The optimal use of bevacizumab in recurrent glioblastoma (GBM), including the choice of monotherapy or combination therapy, remains uncertain. The purpose of this study was to compare combination therapy with bevacizumab monotherapy. METHODS: This was a 2-part randomized phase 2 study. Eligibility criteria included recurrent GBM after radiotherapy and temozolomide, no other chemotherapy for GBM, and Eastern Cooperative Oncology Group performance status 0-2. The primary objective (Part 1) was to determine the effect of bevacizumab plus carboplatin versus bevacizumab monotherapy on progression-free survival (PFS) using modified Response Assessment in Neuro-Oncology criteria. Bevacizumab was given every 2 weeks, 10 mg/kg; and carboplatin every 4 weeks, (AUC 5). On progression, patients able to continue were randomized to continue or cease bevacizumab (Part 2). Secondary endpoints included objective radiological response rate (ORR), quality of life, toxicity, and overall survival (OS). RESULTS: One hundred twenty-two patients (median age, 55y) were enrolled to Part 1 from 18 Australian sites. Median follow-up was 32 months, and median on-treatment time was 3.3 months. Median PFS was 3.5 months for each arm (hazard ratio [HR]: 0.92, 95% CI: 0.64-1.33, P = .66). ORR was 14% (combination) versus 6% (monotherapy) (P = .18). Median OS was 6.9 (combination) versus 7.5 months (monotherapy) (HR: 1.18, 95% CI: 0.82-1.69, P = .38). The incidence of bevacizumab-related adverse events was similar to prior literature, with no new toxicity signals. Toxicities were higher in the combination arm. Part 2 data (n = 48) will be reported separately. CONCLUSIONS: Adding carboplatin resulted in more toxicity without additional clinical benefit. Clinical outcomes in patients with recurrent GBM treated with bevacizumab were inferior to those in previously reported studies. CLINICAL TRIALS REGISTRATION NR: ACTRN12610000915055.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nov104

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials

    Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902 · cited 1×

    “Traditionally used chemotherapy drugs have included carboplatin, lomustine, carmustine, and temozolomide in various schedules, with typical response rates less than 20%, 6-month progression-free survival (6PFS) around 15%, and overall survival (OS) generally less than 6 months, although results across studies are some…”
    Background

Show all 1 references

Cited by

See all 160

Metadata

Authors
Field, K. M., Simes, J., Nowak, A. K., Cher, L., Wheeler, H., Hovey, E. J., Brown, C. S. B., Barnes, E. H., Sawkins, K., Livingstone, A., Freilich, R., Phal, P. M., Fitt, G., CABARET/COGNO investigators, & Rosenthal, M. A.
Venue
Neuro-Oncology
Published
2015-06-30
Volume
17
Issue
11
Pages
1504-1513
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W1933614403
Cited by
160
References
1
FWCI
6.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. https://app.cochat.ai/papers/10.1093/neuonc/nov104
The paper
Field, K. M., Simes, J., Nowak, A. K., Cher, L., Wheeler, H., Hovey, E. J., Brown, C. S. B., Barnes, E. H., Sawkins, K., Livingstone, A., Freilich, R., Phal, P. M., Fitt, G., CABARET/COGNO investigators, & Rosenthal, M. A. (2015). Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/nov104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.